An estimated 20–25% of the population is affected by chronic, non-communicable
inflammatory skin diseases. Chronic skin inflammation has many causes. Among the most …

Bullous pemphigoid is the most frequent autoimmune bullous disease and mainly affects
elderly individuals. Increase in incidence rates in the past decades has been attributed to …

Background Bullous pemphigoid (BP) is the most common autoimmune subepidermal
blistering disease of the skin and mucous membranes. This disease typically affects the …

Immune checkpoint inhibitors have proven to be efficacious for a broad spectrum of solid
organ malignancies. These monoclonal antibodies lead to cytotoxic T-cell activation and …

Autoimmune subepidermal blistering diseases of the skin and mucosae constitute a large
group of sometimes devastating diseases, encompassing bullous pemphigoid, gestational …

Autoimmune bullous disorders are a heterogeneous spectrum of skin disorders
characterized by the production of autoantibodies against adhesion molecules of the skin …

Epidermolysis bullosa acquisita (EBA) is an orphan autoimmune disease. Patients with EBA
suffer from chronic inflammation as well as blistering and scarring of the skin and mucous …

The present S2K guidelines are an update of the most recent edition of the German
guidelines from 2015 [1, 2]. The complete guidelines (including methodology) are available …

Doxycycline, a tetracycline antibiotic, is widely used in the field of dermatology for its
antibiotic properties, anti‐inflammatory properties and good safety profile. Over the past …

IL-17A has been identified as key regulatory molecule in several autoimmune and chronic
inflammatory diseases followed by the successful use of anti-IL-17 therapy, eg in ankylosing …